PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a report published on Friday morning,Benzinga reports. They currently have a $21.00 price objective on the stock.

PDSB has been the topic of several other research reports. Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. StockNews.com downgraded shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, November 9th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $12.33.

PDS Biotechnology Stock Performance

NASDAQ:PDSB opened at $2.01 on Friday. The stock has a market capitalization of $74.01 million, a P/E ratio of -1.73 and a beta of 1.93. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.84 and a current ratio of 3.84. PDS Biotechnology has a fifty-two week low of $1.53 and a fifty-two week high of $6.85. The company has a 50 day moving average price of $3.21 and a 200 day moving average price of $3.26.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Tempus Wealth Planning LLC purchased a new stake in PDS Biotechnology in the second quarter valued at $55,000. Ground Swell Capital LLC purchased a new stake in shares of PDS Biotechnology in the 2nd quarter valued at about $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in PDS Biotechnology during the 2nd quarter worth approximately $115,000. Squarepoint Ops LLC purchased a new position in PDS Biotechnology during the 2nd quarter worth approximately $120,000. Finally, Cubist Systematic Strategies LLC acquired a new position in PDS Biotechnology during the second quarter worth approximately $146,000. 26.84% of the stock is owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.